Market Place
Sourcing Support
All News #Library
Biotech
Amphista Therapeutics Unveils Preclinical Data On SMARCA2
24 Apr 2026 //
GLOBENEWSWIRE
Amphista Unveils AMX-883, DCAF16 Degrader At AACR 2026
21 Apr 2026 //
FIRSTWORD PHARMA
Amphista Therapeutics Presents Next-Gen Targeted Glue Degrader
23 Mar 2026 //
GLOBENEWSWIRE
Amphista Therapeutics Shows Eclipsys Platform Progress
26 Feb 2026 //
GLOBENEWSWIRE
Amphista Therapeutics Unveils AMX-883`s Potential In AML
08 Dec 2025 //
GLOBENEWSWIRE
Amphista Therapeutics Unveils AMX-883 Data At ASH Conference
25 Nov 2025 //
GLOBENEWSWIRE
Amphista Therapeutics Showcases Targeted Glue Tech at Summit
28 Oct 2025 //
GLOBENEWSWIRE
Amphista Shows BRD9 Degradation via DCAF16 in Nature Journal
27 Oct 2025 //
GLOBENEWSWIRE
Amphista Appoints Leaders To Advance Glue Protein degraders
23 Oct 2025 //
GLOBENEWSWIRE
Amphista Therapeutics Nominates AMX-883, For Myeloid leukaemia
15 Oct 2025 //
GLOBENEWSWIRE
Amphista Therapeutics Reveals Tead Targeted Glue™ Program
23 Sep 2025 //
GLOBENEWSWIRE
Amphista Therapeutics Reveals SMARCA2 Degrader Program Details
17 Sep 2025 //
GLOBENEWSWIRE
Amphista Presents Cryo-EM platform at SLAS Europe 2025
22 May 2025 //
GLOBENEWSWIRE
Amphista Therapeutics to present novel BRD9 degradation mechanism
20 Mar 2025 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.